Breast and
Ovarian cancer

Detect. Diagnose. Do

Discover the risk

Breast cancer is the most common form of cancer in women and the leading cause of cancer-related death. Ovarian cancer is the deadliest gynecological cancer, with a five-year survival rate of 45 percent.

Know the risk

In both diseases, family history can be a significant risk factor. Next-generation DNA testing can detect hereditary breast and ovarian cancer risk.

Address the risk

Diagnostic tests identify women with elevated risk who may benefit from risk-reducing strategies such as prophylactic surgery, hormone replacement therapy or targeted treatment using PARP inhibitors such as LynparzaTM (olaparib).

Think inside the box

Devyser BRCA and Devyser HBOC kits are rapid, targeted NGS library preparation assays that detect variants in BRCA1, BRCA2 and 12 additional genes where mutations are known to significantly increase the risk of developing breast and ovarian cancer.

The tests are fast and easy to use. The CE-IVD solution is end-to-end – from sample to result. This saves time, is easy to implement and is simple to replicate.

A short handling time of 45 minutes increases lab productivity, freeing up technicians to run more tests in a given time frame.

The kits use somatic mutation analysis to detect women who may benefit from targeted treatments.

Our Devyser HBOC kit can also be used as a standalone follow-up after negative BRCA testing with Devyser BRCA.